PGR and breast carcinoma: Several studies have evaluated the correlation of PIK3CA mutations with clinicopathological parameters such as estrogen receptor (ER)/progesterone receptor (PR) positivity, the presence of lymph node metastases, and response to therapy in breast cancers (Table 1).